Melanoma Cutaneous Malignant Susceptibility To 5 C2751295
A genetic susceptibility factor associated with increased risk of developing cutaneous malignant melanoma. Regular skin exams and sun avoidance are recommended.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Sun Safety Education Program
Structured education on UV protection strategies, indoor tanning risks, and environmental sun awareness integrated into daily routines.
Serial Digital Dermoscopy Imaging
Total body photography and serial dermoscopy imaging to track existing nevi over time and identify any changes suggesting malignant transformation.
Additional treatment options
Wide Local Excision
Standard surgical excision with recommended margins for confirmed melanoma or high-grade dysplasia, following current oncology guidelines.
surgicalSkin Health Supplement Consultation
Evaluation and guidance on complementary supplements such as vitamin D, nicotinamide, and omega-3 fatty acids that may support skin cell integrity.
complementaryBiopsy of Suspicious Lesions
Punch or shave biopsy of any lesion demonstrating concerning ABCDE characteristics or changes on sequential monitoring.
procedureWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Melanoma Cutaneous Malignant Susceptibility To 5 C2751295?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005.
Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012.
Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015.
Zhou R, Chan E, Schweitzer T, et al. Genetic predisposition to cutaneous malignant melanoma: a systematic review and meta-analysis. J Clin Oncol. 2021.
Medication Comparisons
Compare medications used to treat Melanoma Cutaneous Malignant Susceptibility To 5 C2751295. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy